Haiyan Li, Cardiologist, Director of Drug Clinical Trial Center(DCTC), Peking University Third Hospital

Clinical Specialty

With over three decades of practice in cardiology, Professor Li possesses extensive clinical experience in the diagnosis and treatment of cardiovascular diseases including hypertension, coronary heart disease, hyperlipidemia, heart failure, and emergency treatment. She also has great clinical experience in the assessment and treatment of cardiovascular toxicity for patients with cancers.

Clinical Research Experience

Professor Li has been in charge of DCTC since 2006.  As the project leader, she gained support from the GCP platform related to Innovative Drug Research & Development, a major national science and technology project during the Eleventh, Twelfth, and Thirteenth Five-Year Plans. Under her leadership, DCTC built an international and professional Phase I Clinical Research Ward, with high quality and high efficiency operation model.

Throughout over two decades of engagement in clinical trials, DCTC has managed more than 2,000 clinical trials of new drugs and medical devices, over 950 of which are ongoing ones. Professor Li is highly experienced in the decision-making of new drugs and medical devices clinical development, study design, ethical review, operation and quality control of clinical trials.  As a principal investigator for Phase I clinical trials, she focuses on the early-phase research of innovative drugs, including those on cardiovascular and metabolic diseases, and the cardiac safety assessment of innovative drugs.

Professional Commitments Outside Main Duties

Professor Li assumed the position of Member of the Cardiovascular and Renal Diseases Clinical Expert Advisory Committee of the National Medical Products Administration(NMPA) in 2018 and participated in the review of new drugs and the development of relevant guidelines. She is also a member of ICH E6, E8, E14, and E17 China Working Group and ICH E6 and E21 Global Expert Working Group and serves as the Chair of the Committee of Experts of the Beijing Association of Oncology.